## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Canceled)
- 2. (Currently Amended) A method for treating of a motoneuron disease in a patient in need thereof by increasing the survival and/or growth of motoneurons in said patient comprising administering to the said patient a pharmaceutically effective amount of a low molecular weight heparin.
- (Original) The method according to claim 2 wherein the motoneuron disease is amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy or lateral sclerosis.
- 4. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin has a mean molecular weight of between 1000 and 10000 daltons.
- 5. (Original) The method according to claim 4, wherein the low molecular weight heparin has a mean molecular weight of between 1500 and 6000 daltons.
- 6. (Original) The method according to claim 4, wherein the low molecular weight heparin has a mean molecular weight of between 4000 and 5000 daltons.
- 7. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin consists of oligosaccharides having a 2-O-sulfo-4-enopyranosuronic acid at one of their ends.
- 8. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is obtained by depolymerization of a heparin ester using a base.

- 9. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is enoxaparin.
- 10. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is nadroparin.
- 11. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is parnaparin.
- 12. (Currently Amended) The method according to one of claims 1-to-2 or 3, wherein the low molecular weight heparin is reviparin.
- 13. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is dalteparin.
- 14. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is tinzaparin.
- 15. (Currently Amended) The method according to one of claims 1-te-2 or 3, wherein the low molecular weight heparin is danaparoid.
- 16. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is ardeparin.
- 17. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is certoparin.
- 18. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is CY222.
- 19. (Currently Amended) The method according to one of claims 1 to 2 or 3, wherein the low molecular weight heparin is SR90107/ORG31540.